Delving into the Latest Updates on KT-6352 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

6-Methylstaurosporin

Target

PKC x TPO receptor

Action

inhibitors, agonists

Mechanism

PKC inhibitors(Protein kinase C inhibitors), TPO receptor agonists(Thrombopoietin receptor agonists)

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Thrombocytopenia

Originator Organization

Kyowa Hakko Kogyo Co., Ltd.

Active Organization-

Inactive Organization

Kyowa Hakko Kogyo Co., Ltd.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

We investigated the in vitro and in vivo effects of KT6352, a derivative of indolocarbazole compound, on murine megakaryocytopoiesis. When serum-free megakaryocyte (Meg) colony assay was performed with 100 U/mL of recombinant mouse interleukin-3 (rmIL-3), the addition of 1x10(-11)M to 1x10(-9)M of KT6352 increased the number of Meg colonies. An additional increase of Meg colonies by KT6352 was observed in the serum-free culture containing rmIL-3 plus recombinant mouse interleukin-6 or rmIL-3 plus recombinant mouse stem cell factor. KT6352 did not stimulate Meg colony formation without rmIL-3. When KT6352 was administered intraperitoneally to normal BALB/c male mice at a dose of 10 mg/kg daily for 5 consecutive days, a 2.1-fold increase in the platelet count was observed on day 14, and the prolonged thrombocytopoiesis was detectable from 9 to 27 days after KT6352 administration. A marked increase in the white blood cell count was also observed from 5 to 14 days after KT6352 treatment. Before the gradual increase of platelet counts, 8 days after KT6352 administration, a marked increase in the number of colony-forming units of megakaryocytes (CFU-Megs) in bone marrow and spleen was observed, and a substantial increase in the number of splenic CFU-Megs was observed 14 and 23 days after KT6352 administration. Bone marrow Meg ploidy analysis by two-color flow cytometry showed a shift in the modal ploidy class from 16 to 32 and an increase in the frequency of 64 cells in KT6352-treated mice. These results suggest a possible therapeutic benefit of KT6352 in the management of thrombocytopenia.

100 Deals associated with KT-6352

Login to view more data